http://orcid.org/0000-0002-2600-4021
References
- Silverberg NB. Pediatric Molluscum Contagiosum; Optimal treatment strategies. Pediatr Drugs. 2003;5:505–512.
- Kakourou T, Zachariades A, Anastasiou T. Molluscum contagiosum in Greek children: a case series. Int J Dermatol. 2005;44:221–223.
- Farhangian ME, Huang KE, Feldman SR, et al. Treatment of Molluscum Contagiosum with Imiquimod in the United States: a retrospective cross-sectional study. Pediatr Dermatol. 2016;33:227–228.
- Leung AKC, Barankin B, Hon KLE. Molluscum Contagiosum: an update. Recent Pat Inflamm Allergy Drug Discov. 2017;11:22–31.
- Pompei DT, Rezzadeh KS, Viola KV, et al. Cantharidin therapy: practice patterns and attitudes of health care providers. J Am Acad Dermatol. 2013;68:1045–1046.
- Coloe J, Morrell DS. Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum. Pediatr Dermatol. 2009;26:405–408.
- Bertaux B, Prost C, Heslan M, et al. Cantharide acantholysis: endogenous protease activation leading to desmosomal plaque dissolution. Br J Dermatol. 1988;118:157–165.
- Vakharia PP, Chopra R, Silverberg NB, et al. Silverberg JIEfficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. Am J Clin Dermatol. 2018;19:791–803.
- Enns LL, Evans MS. Intralesional immunotherapy with candida antigen for the treatment of molluscum contagiosum in children. Pediatr Dermatol. 2011;28:254–258.
- Na CH1, Kim DJ, Kim MS, et al. Successful treatment of molluscum contagiosum with intralesional immunotherapy by measles, mumps, and rubella vaccine: a report of two cases. Dermatol Ther. 2014;27:373–376.
- Chandra S, Sil A, Datta A, et al. A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral warts. Indian J Dermatol Venereol Leprol. 2019;85:355–366.
- Elela IM, Elshahid AR, Mosbeh AS. Intradermal vs. intralesional purified protein derivatives in treatment of warts. Golf J Deramatol Venereol. 2011;18:21–26.
- Wananukul S, Chatproedprai S, Kittiratsacha P. Intralesional immunotherapy using tuberculin PPD in the treatment of palmoplantar and periungual warts. Asian Biomed. 2009;3:739–743.
- Osier E, Eichenfield LF. The utility of cantharidin for the treatment of molluscum contagiosum. Pediatr Dermatol. 2015;32:295.
- Sharma P, Mukherjee R, Talwar GP, et al. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev. 2005;76:127–143.
- Amirnia M, Khodaeiani E, Fouladi DF, et al. Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: a randomized, placebo-controlled, double-blind clinical trial including an extra group of candidates for cryotherapy. J Dermatolog Treat. 2016;27:173–178.
- Saoji V, Lade NR, Gadegone R, et al. Immunotherapy using purified protein derivative in the treatment of warts: an open uncontrolled trial. Indian J Dermatol Venereol Leprol. 2016;82:42–46.
- Abd-Elazeim FM, Mohammed GF, Fathy A, et al. Evaluation of IL- 12 serum level in patients with recalcitrant multiple common warts, treated by intralesional tuberculin antigen. J Dermatolog Treat. 2014;25:264–267.
- Eassa BI, Abou-Bakr AA, El-Khalawany MA. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther. 2011;24:137–143.
- Lahti A, Hannuksela M. Topical immunotherapy with tuberculin jelly for common warts. Arch Dermatol Res. 1982;273:153–154.
- Abo Elela IM, Elshahid MD, Mosbeh AR, et al. Intradermal vs intralesional purified protein derivatives in treatment of warts. Gulf J Dermatol Venereol. 2011;18:21–26.